Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced that a Biologics License Application has been submitted to the United States Food and Drug Administration for vedolizumab, an investigational humanized monoclonal antibody for the treatment of adults with moderately to ... (more)
More...
More...